Sign In
Buy NKTR
$72.76
+2.17 (+3.07%)
At Close: Aug 04, 2026
Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of Phase 1 clinical data for its lead immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) in combination with nivolumab,
Patent Filings Roundup: The Return of the Founder, Retailers Target Wireless LLC, European NPE Revives 2G/3G Patent Wars
04:15pm, Wednesday, 20'th May 2020
There were only 16 new patent filings at the Patent Trial and Appeal Board (PTAB)—all inter partes reviews (IPRs)—this week, with a whopping 70 new district court complaints filed.
Wolf's Corona Discounts: Bristol-Myers Squibb (NYSE:BMY)
02:33pm, Tuesday, 19'th May 2020
It's finally time to write about my favorite pharma stock in the corona-discount model. Bristol-Myers Squibb has gone from being a rather insignificant holding
Oppenheimer Maintains Perform on Nektar Therapeutics, Raises Price Target to $25
12:23pm, Monday, 18'th May 2020Is There An Opportunity With Nektar Therapeutics's (NASDAQ:NKTR) 46% Undervaluation?
12:05pm, Monday, 18'th May 2020
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Nektar Therapeutics...
Oppenheimer Sticks to Their Hold Rating for Nektar Therapeutics
11:13pm, Sunday, 17'th May 2020
Oppenheimer analyst Jay Olson maintained a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Sunday, setting a price target of $25, which is approximately 13.53% above the present share price of $22
8-K: BioXcel Therapeutics, Inc.
03:39am, Wednesday, 13'th May 2020
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange...
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2020 Results - Earnings Call Transcript
07:02pm, Tuesday, 12'th May 2020
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2020 Results Conference Call May 12, 2020 08:30 AM ET Company Participants Vimal Mehta - Founder and CEO Richard Ste
HC Wainwright & Co. Reiterates Neutral on Nektar Therapeutics, Lowers Price Target to $26
11:09am, Tuesday, 12'th May 2020H.C. Wainwright Sticks to Their Hold Rating for Nektar Therapeutics
10:27am, Tuesday, 12'th May 2020
H.C. Wainwright analyst Debjit Chattopadhyay reiterated a Hold rating on Nektar Therapeutics (NASDAQ:NKTR) on Tuesday, setting a price target of $26, which is approximately 25.18% above the present sh
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.45%
12:00am, Monday, 11'th May 2020
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.45%
SVB Leerink Maintains Market Perform on Nektar Therapeutics, Raises Price Target to $18
03:19pm, Friday, 08'th May 2020Nektar's (NKTR) Q1 Earnings and Revenues Top Estimates
02:29pm, Friday, 08'th May 2020
Nektar (NKTR) reports encouraging first-quarter 2020 results. The company continues to progress with its pipeline candidates.
